Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2018 1
2019 3
2020 10
2021 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the VEGF Pathway in Osteosarcoma.
Assi T, Watson S, Samra B, Rassy E, Le Cesne A, Italiano A, Mir O. Assi T, et al. Among authors: samra b. Cells. 2021 May 18;10(5):1240. doi: 10.3390/cells10051240. Cells. 2021. PMID: 34069999 Free PMC article. Review.
Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Sasaki K, et al. Among authors: samra b. Cancer. 2021 Aug 1;127(15):2648-2656. doi: 10.1002/cncr.33529. Epub 2021 Apr 1. Cancer. 2021. PMID: 33793964 Free article.
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver N. Alotaibi AS, et al. Among authors: samra b. Blood Cancer Discov. 2021 Mar;2(2):125-134. doi: 10.1158/2643-3230.BCD-20-0143. Epub 2020 Dec 6. Blood Cancer Discov. 2021. PMID: 33681815 Free PMC article.
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Shoukier M, et al. Among authors: samra b. Cancer. 2021 Feb 1;127(3):381-390. doi: 10.1002/cncr.33293. Epub 2020 Oct 29. Cancer. 2021. PMID: 33119202 Free article.
Should we screen patients with hematologic malignancies for COVID-19?
Rassy E, Khoury-Abboud RM, Ibrahim N, Assi T, Samra B, Hanna C, Karak FE, Ghosn M. Rassy E, et al. Among authors: samra b. Hematol Oncol. 2020 Dec;38(5):648-653. doi: 10.1002/hon.2780. Epub 2020 Aug 8. Hematol Oncol. 2020. PMID: 32779823 Free PMC article. Review.
20 results